Study people who took palbociclib prescriptions
Treatments studied
Part of Cancer, Skin clinical trials.
This study uses prescription records to learn about real-world use of palbociclib (a cancer medicine). You may be included if you’re an adult and have filled at least one palbociclib prescription.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have filled at least one prescription for palbociclib.
- You will be included based on pharmacy prescription records.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well the drug Palbociclib works for Egyptian patients with metastatic breast cancer. It looks at how genes may affect treatment response.
This trial tests a drug called palbociclib for people with advanced liver cancer who have already tried at least two other treatments. The goal is to see if palbociclib can help shrink the cancer or slow its growth.
This trial looks at why some patients with hormone-positive, HER2-negative metastatic breast cancer develop low white blood cells (neutropenia) when taking the drug palbociclib. It aims to find risk factors and check how well the treatment works.
This trial studies how well different doses of CDK4/6 inhibitors (palbociclib or ribociclib) work in people aged 65 or older with HR+/HER2- metastatic breast cancer. It aims to find the best starting dose to balance effectiveness and side effects.
This trial tests an oral “CDK” medicine in people with triple-negative breast cancer who are about to receive standard treatment. It’s designed to help researchers see whether the drug can control or improve the cancer early, using planned biopsies and scans.
This trial tests if a higher dose of palbociclib together with hydroxychloroquine and hormone therapy works better than the standard dose of palbociclib with hormone therapy. It is for people with hormone receptor-positive, HER2-negative breast cancer that has spread and has not been treated yet.
Hear when a new Malignant Neoplasm of Breast trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.